课题基金 / 基金详情

项目摘要

项目成果

Theodore S Jardetzky的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 大多数过敏反应是由免疫球蛋白E(IgE)抗体引起的,这种抗体是针对过敏原的 触发由肥大细胞和嗜碱性粒细胞介导的强烈炎症反应。免疫球蛋白与高亲和力结合 受体(FcεRI)在这些过敏效应细胞上表达,使这一共同的中枢相互作用 不同的过敏原特异性反应。抗IgE抗体(奥马珠单抗)目前用于治疗过敏 哮喘和慢性特发性荨麻疹,证明抑制Ig E:FcεRI相互作用的可行性 治疗效果。我们已经开发了多种方法来识别IgE的小分子配体 并为进一步研究确定了有希望的线索。在这项建议中,我们将进一步调查这些线索,以 探索生产新的免疫球蛋白E功能和抑制探针的可能性。 好了!
英文摘要
Project Summary Most allergic reactions are caused by immunoglobulin E (IgE) antibodies that are specific for allergens and that trigger potent inflammatory responses mediated by mast cells and basophils. IgE binds to the high affinity receptor (FcεRI) expressed on these allergic effector cells, making this a central interaction that is common to different allergen-specific responses. The anti-IgE antibody (omalizumab) is currently used to treat allergic asthma and chronic idiopathic urticaria, demonstrating the feasibility of inhibiting the IgE:FcεRI interaction for therapeutic benefit. We have developed multiple approaches to identifying small molecule ligands for the IgE and identified promising leads for further studies. In this proposal, we will further investigate these leads to explore the possibility of producing novel probes for IgE function and inhibition. !
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery and engineering of novel anti-IgE disruptive inhibitors
  • 批准号:
    10353982
  • 项目类别:
  • 资助金额:
    $23.61万
  • 财政年份:
    2021
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
Discovery and engineering of novel anti-IgE disruptive inhibitors
  • 批准号:
    10495213
  • 项目类别:
  • 资助金额:
    $19.68万
  • 财政年份:
    2021
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
  • 批准号:
    10468251
  • 项目类别:
  • 资助金额:
    $75.42万
  • 财政年份:
    2020
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
  • 批准号:
    10120270
  • 项目类别:
  • 资助金额:
    $76.77万
  • 财政年份:
    2020
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
海外基金